 Stacie Daugherty
Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2024 | 1250 | 2.490 |
Why?
| | Out-of-Hospital Cardiac Arrest | 6 | 2024 | 123 | 2.090 |
Why?
| | Healthcare Disparities | 11 | 2021 | 674 | 1.920 |
Why?
| | Antihypertensive Agents | 8 | 2021 | 508 | 1.840 |
Why?
| | Sex Factors | 23 | 2024 | 2055 | 1.820 |
Why?
| | Cardiopulmonary Resuscitation | 6 | 2024 | 332 | 1.680 |
Why?
| | Medication Adherence | 5 | 2022 | 510 | 1.420 |
Why?
| | Exercise Test | 5 | 2017 | 620 | 1.270 |
Why?
| | Myocardial Infarction | 11 | 2017 | 1066 | 1.140 |
Why?
| | Cardiology | 7 | 2024 | 286 | 1.110 |
Why?
| | Cardiovascular Diseases | 8 | 2026 | 2091 | 0.940 |
Why?
| | Racism | 4 | 2021 | 141 | 0.920 |
Why?
| | Registries | 20 | 2022 | 2205 | 0.850 |
Why?
| | Heart Failure | 8 | 2022 | 2096 | 0.830 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1546 | 0.810 |
Why?
| | Coronary Disease | 3 | 2011 | 373 | 0.810 |
Why?
| | Blood Pressure | 5 | 2019 | 1740 | 0.780 |
Why?
| | Social Values | 2 | 2021 | 38 | 0.740 |
Why?
| | Risk Assessment | 7 | 2022 | 3522 | 0.720 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 197 | 0.680 |
Why?
| | Defibrillators, Implantable | 6 | 2019 | 318 | 0.680 |
Why?
| | Cardiologists | 2 | 2018 | 46 | 0.680 |
Why?
| | Multimodal Imaging | 5 | 2024 | 119 | 0.640 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2020 | 83 | 0.610 |
Why?
| | Myocardial Ischemia | 3 | 2022 | 279 | 0.610 |
Why?
| | Adrenergic beta-Antagonists | 5 | 2018 | 227 | 0.580 |
Why?
| | Public Opinion | 1 | 2019 | 60 | 0.580 |
Why?
| | United States | 33 | 2025 | 15298 | 0.580 |
Why?
| | Death, Sudden, Cardiac | 4 | 2015 | 193 | 0.570 |
Why?
| | Primary Prevention | 4 | 2015 | 202 | 0.560 |
Why?
| | Attitude to Health | 1 | 2021 | 451 | 0.560 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 874 | 0.560 |
Why?
| | Middle Aged | 35 | 2026 | 34658 | 0.550 |
Why?
| | Female | 56 | 2026 | 75814 | 0.550 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 179 | 0.550 |
Why?
| | Clinical Decision-Making | 2 | 2018 | 341 | 0.540 |
Why?
| | Risk Factors | 18 | 2025 | 10490 | 0.540 |
Why?
| | Male | 50 | 2026 | 70140 | 0.530 |
Why?
| | Humans | 71 | 2026 | 141284 | 0.500 |
Why?
| | Thromboembolism | 1 | 2017 | 126 | 0.490 |
Why?
| | Anemia | 1 | 2017 | 175 | 0.490 |
Why?
| | Warfarin | 1 | 2017 | 168 | 0.490 |
Why?
| | Hospitalization | 3 | 2025 | 2264 | 0.480 |
Why?
| | Disease Management | 2 | 2019 | 634 | 0.480 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 305 | 0.480 |
Why?
| | Patient Discharge | 5 | 2022 | 915 | 0.470 |
Why?
| | Follow-Up Studies | 13 | 2022 | 5222 | 0.470 |
Why?
| | Hemoglobins | 1 | 2017 | 361 | 0.460 |
Why?
| | Anticoagulants | 2 | 2018 | 724 | 0.460 |
Why?
| | Coronary Artery Disease | 5 | 2022 | 716 | 0.450 |
Why?
| | Ultrasonography | 1 | 2019 | 765 | 0.440 |
Why?
| | Atrial Fibrillation | 2 | 2018 | 501 | 0.440 |
Why?
| | Stroke | 4 | 2024 | 1199 | 0.430 |
Why?
| | Percutaneous Coronary Intervention | 3 | 2017 | 489 | 0.430 |
Why?
| | Aged | 27 | 2026 | 24836 | 0.430 |
Why?
| | Quality of Health Care | 2 | 2020 | 645 | 0.430 |
Why?
| | American Heart Association | 5 | 2020 | 299 | 0.420 |
Why?
| | Sleep | 2 | 2022 | 882 | 0.410 |
Why?
| | Guideline Adherence | 1 | 2018 | 560 | 0.410 |
Why?
| | Practice Patterns, Physicians' | 3 | 2018 | 1336 | 0.410 |
Why?
| | Ambulatory Care | 1 | 2018 | 592 | 0.400 |
Why?
| | Sex Distribution | 5 | 2020 | 381 | 0.400 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2210 | 0.400 |
Why?
| | Hemostasis, Surgical | 1 | 2013 | 27 | 0.400 |
Why?
| | Aged, 80 and over | 11 | 2026 | 7948 | 0.390 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 449 | 0.370 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 112 | 0.370 |
Why?
| | Postoperative Hemorrhage | 1 | 2013 | 88 | 0.370 |
Why?
| | Health Status Disparities | 3 | 2021 | 303 | 0.360 |
Why?
| | Drug Resistance | 1 | 2012 | 149 | 0.360 |
Why?
| | Patient Selection | 2 | 2013 | 685 | 0.300 |
Why?
| | Alaska Natives | 2 | 2022 | 154 | 0.300 |
Why?
| | Adult | 21 | 2026 | 39319 | 0.300 |
Why?
| | Resuscitation Orders | 2 | 2020 | 46 | 0.300 |
Why?
| | Patient Preference | 1 | 2011 | 204 | 0.290 |
Why?
| | Multivariate Analysis | 4 | 2017 | 1505 | 0.280 |
Why?
| | Electrocardiography | 1 | 2011 | 626 | 0.270 |
Why?
| | Incidence | 7 | 2022 | 2809 | 0.270 |
Why?
| | Societies, Medical | 4 | 2024 | 859 | 0.270 |
Why?
| | Cardiac Catheterization | 1 | 2011 | 543 | 0.260 |
Why?
| | Risk Reduction Behavior | 2 | 2026 | 227 | 0.250 |
Why?
| | Cohort Studies | 7 | 2025 | 5809 | 0.250 |
Why?
| | Aspirin | 2 | 2017 | 388 | 0.250 |
Why?
| | Coronary Angiography | 1 | 2008 | 316 | 0.240 |
Why?
| | Indians, North American | 2 | 2022 | 655 | 0.240 |
Why?
| | Young Adult | 12 | 2026 | 13727 | 0.240 |
Why?
| | Lung | 1 | 2019 | 4051 | 0.240 |
Why?
| | Thoracic Surgery | 2 | 2017 | 141 | 0.230 |
Why?
| | Continuity of Patient Care | 1 | 2008 | 282 | 0.230 |
Why?
| | Heart Diseases | 2 | 2019 | 337 | 0.230 |
Why?
| | Retrospective Studies | 14 | 2024 | 16447 | 0.230 |
Why?
| | Heart Arrest | 2 | 2020 | 397 | 0.220 |
Why?
| | Insurance, Health | 2 | 2025 | 296 | 0.220 |
Why?
| | Heart-Assist Devices | 2 | 2022 | 561 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 19 | 0.210 |
Why?
| | Secondary Prevention | 2 | 2017 | 241 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2024 | 1395 | 0.200 |
Why?
| | Text Messaging | 1 | 2026 | 179 | 0.200 |
Why?
| | Prospective Studies | 7 | 2019 | 7805 | 0.200 |
Why?
| | Housing | 1 | 2024 | 146 | 0.200 |
Why?
| | Odds Ratio | 5 | 2017 | 1057 | 0.190 |
Why?
| | Migraine Disorders | 1 | 2024 | 106 | 0.190 |
Why?
| | Prognosis | 6 | 2019 | 4080 | 0.180 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 77 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2026 | 342 | 0.180 |
Why?
| | Women's Health | 2 | 2016 | 308 | 0.170 |
Why?
| | Peptide Fragments | 2 | 2017 | 696 | 0.170 |
Why?
| | Single-Blind Method | 1 | 2021 | 289 | 0.170 |
Why?
| | Self Report | 2 | 2022 | 859 | 0.170 |
Why?
| | Hospital Mortality | 4 | 2018 | 938 | 0.170 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 149 | 0.160 |
Why?
| | Writing | 1 | 2021 | 99 | 0.160 |
Why?
| | Telephone | 1 | 2021 | 181 | 0.160 |
Why?
| | Health Behavior | 1 | 2026 | 784 | 0.160 |
Why?
| | Treatment Outcome | 10 | 2017 | 11216 | 0.160 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1043 | 0.150 |
Why?
| | Sex Characteristics | 5 | 2022 | 783 | 0.150 |
Why?
| | Survival Rate | 5 | 2020 | 1979 | 0.150 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2019 | 12 | 0.150 |
Why?
| | Sexuality | 1 | 2019 | 30 | 0.150 |
Why?
| | Electric Countershock | 1 | 2019 | 115 | 0.150 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2019 | 54 | 0.150 |
Why?
| | Clinical Audit | 1 | 2018 | 13 | 0.140 |
Why?
| | Prevalence | 3 | 2024 | 2795 | 0.140 |
Why?
| | Colorado | 3 | 2021 | 4599 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2020 | 223 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 57 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.140 |
Why?
| | Time Factors | 6 | 2018 | 6951 | 0.140 |
Why?
| | Logistic Models | 4 | 2012 | 2098 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2069 | 0.140 |
Why?
| | Postmenopause | 1 | 2020 | 369 | 0.140 |
Why?
| | Atherosclerosis | 1 | 2022 | 402 | 0.140 |
Why?
| | F Factor | 1 | 2017 | 3 | 0.140 |
Why?
| | Patient Readmission | 2 | 2020 | 698 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 309 | 0.130 |
Why?
| | Residence Characteristics | 1 | 2020 | 367 | 0.130 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 2 | 2017 | 38 | 0.130 |
Why?
| | Ezetimibe | 1 | 2017 | 25 | 0.130 |
Why?
| | Transgender Persons | 1 | 2020 | 201 | 0.130 |
Why?
| | Simvastatin | 1 | 2017 | 62 | 0.130 |
Why?
| | Health Care Surveys | 1 | 2019 | 561 | 0.130 |
Why?
| | Point-of-Care Systems | 1 | 2019 | 189 | 0.130 |
Why?
| | Poverty | 1 | 2020 | 527 | 0.130 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2017 | 104 | 0.130 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 526 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 99 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 153 | 0.120 |
Why?
| | Sex Offenses | 1 | 2019 | 201 | 0.120 |
Why?
| | Mortality | 2 | 2008 | 359 | 0.120 |
Why?
| | Blood Pressure Determination | 2 | 2014 | 144 | 0.120 |
Why?
| | Anticholesteremic Agents | 1 | 2017 | 153 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2017 | 329 | 0.110 |
Why?
| | Anesthesiology | 1 | 2017 | 171 | 0.110 |
Why?
| | Administration, Oral | 1 | 2017 | 825 | 0.110 |
Why?
| | Waiting Lists | 1 | 2017 | 245 | 0.110 |
Why?
| | Aortic Valve Stenosis | 1 | 2017 | 246 | 0.110 |
Why?
| | Ambulatory Care Facilities | 2 | 2020 | 245 | 0.110 |
Why?
| | Communication | 2 | 2018 | 941 | 0.110 |
Why?
| | Angiography | 3 | 2020 | 207 | 0.100 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 283 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2017 | 433 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2019 | 802 | 0.100 |
Why?
| | Hirudins | 1 | 2013 | 52 | 0.100 |
Why?
| | Obesity | 2 | 2024 | 3007 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 450 | 0.100 |
Why?
| | Antithrombins | 1 | 2013 | 69 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 880 | 0.090 |
Why?
| | Critical Care | 1 | 2018 | 670 | 0.090 |
Why?
| | Diuretics | 1 | 2012 | 72 | 0.090 |
Why?
| | Hemorrhage | 1 | 2017 | 788 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1490 | 0.090 |
Why?
| | Echocardiography | 3 | 2020 | 647 | 0.090 |
Why?
| | Health Personnel | 1 | 2018 | 727 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 2047 | 0.090 |
Why?
| | Stroke Volume | 1 | 2013 | 598 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 714 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1362 | 0.080 |
Why?
| | Aftercare | 2 | 2022 | 218 | 0.080 |
Why?
| | Age Factors | 4 | 2022 | 3295 | 0.080 |
Why?
| | Biomarkers | 2 | 2017 | 4180 | 0.080 |
Why?
| | Hospitals | 1 | 2014 | 688 | 0.080 |
Why?
| | Eligibility Determination | 1 | 2009 | 69 | 0.070 |
Why?
| | Medicare | 3 | 2022 | 802 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 4 | 2020 | 2765 | 0.070 |
Why?
| | Poisson Distribution | 1 | 2008 | 76 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2008 | 1268 | 0.070 |
Why?
| | Adolescent | 7 | 2026 | 22116 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5653 | 0.060 |
Why?
| | Pregnancy | 1 | 2020 | 7035 | 0.060 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2017 | 209 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1013 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 126 | 0.060 |
Why?
| | Veterans | 1 | 2017 | 1519 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2929 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 367 | 0.050 |
Why?
| | Heart Rate | 1 | 2008 | 835 | 0.050 |
Why?
| | Recovery of Function | 1 | 2008 | 684 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 717 | 0.050 |
Why?
| | Primary Health Care | 1 | 2014 | 1757 | 0.050 |
Why?
| | Pilot Projects | 2 | 2020 | 1820 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2024 | 270 | 0.040 |
Why?
| | Alaska | 1 | 2021 | 85 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 404 | 0.040 |
Why?
| | Gender Identity | 1 | 2020 | 128 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 396 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5948 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2014 | 2529 | 0.040 |
Why?
| | Perception | 1 | 2021 | 375 | 0.040 |
Why?
| | Minority Health | 1 | 2018 | 17 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 219 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 44 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2020 | 614 | 0.030 |
Why?
| | California | 1 | 2019 | 457 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | Advisory Committees | 1 | 2019 | 214 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2017 | 81 | 0.030 |
Why?
| | Europe | 1 | 2017 | 408 | 0.030 |
Why?
| | Exercise | 1 | 2008 | 2113 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2009 | 2831 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 538 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3577 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 342 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 388 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 135 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2390 | 0.030 |
Why?
| | Veterans Health | 1 | 2017 | 186 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 239 | 0.030 |
Why?
| | Frail Elderly | 1 | 2015 | 132 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 855 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1322 | 0.030 |
Why?
| | Caregivers | 1 | 2022 | 940 | 0.030 |
Why?
| | Radial Artery | 1 | 2014 | 69 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 283 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 579 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2017 | 477 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 1 | 2017 | 711 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1035 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2018 | 868 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1671 | 0.020 |
Why?
| | Dementia | 1 | 2015 | 269 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 360 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3345 | 0.020 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 291 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1519 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1178 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 626 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1311 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 176 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 178 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1039 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1078 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3734 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 449 | 0.020 |
Why?
| | Insulin | 1 | 2014 | 2472 | 0.010 |
Why?
| | Child | 1 | 2020 | 22390 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2731 | 0.010 |
Why?
|
|
Daugherty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|